Mechanisms of Diabetic Renal Damage: Role of the Kinin Receptors

糖尿病肾损伤的机制:激肽受体的作用

基本信息

  • 批准号:
    8127025
  • 负责人:
  • 金额:
    $ 4.26万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-08-15 至 2014-08-14
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Bradykinin receptors (B1, B2) are GPCRs that have been implicated in the proliferative and fibrotic response that characterizes diabetic nephropathy. Bradykinin receptor expression is increased in the diabetic glomerulus, and their activation initiates transcription of the pro-fibrotic genes: CTGF and TGF2R1. Co-immunoprecipitation and fluorescent colocalization studies have shown that the B2 receptor forms heterodimers with the angiotensin 2 type 1 (AT1R) receptor on the plasma membrane. AT1-B2 heterodimer formation potentiates calcium signaling which may aggravate the fibrotic response. We hypothesize that elevated expression of the AT1R increases the population of AT1-B2 heterodimers, and promotes bradykinin- independent internalization of B2 receptors by SII[Sar1, Ile4, Ile8]-angiotensin (a peptide antagonist of the AT1R that causes 2-arrestin dependent internalization without coupling to G proteins) but not by losartan (a non-peptide neutral antagonist). In an AT1R tetracycline-inducible HEK cell model, SII pretreatment was a non- competitive antagonist of bradykinin-induced calcium signaling whereas losartan had no effect. Similar results were obtained in primary rat VSMCs. We hypothesize that AT1R antagonists that induce receptor internalization can function as allosteric antagonists of bradykinin signaling in conditions that favor the formation of heterodimers, suggesting their utility in the prevention of diabetic nephropathy progression. PUBLIC HEALTH RELEVANCE: Understanding how diabetes alters the behavior of kidney cells is essential to developing novel therapeutic approaches for the treatment of diabetic kidney disease. This proposal will investigate how receptor-receptor interaction affects cell signaling.
描述(由申请人提供):缓激肽受体(B1,B2)是GPCR,与糖尿病肾病的增殖和纤维化反应有关。缓激肽受体在糖尿病肾小球中表达增加,它们的激活启动促纤维化基因CTGF和TGF 2 R1的转录。免疫共沉淀和荧光共定位研究表明,B2受体与血管紧张素2 1型(AT 1 R)受体在质膜上形成异二聚体。AT 1-B2异源二聚体的形成增强了钙信号传导,这可能加重纤维化反应。我们假设AT 1 R的表达增加了AT 1-B2异二聚体的数量,并通过SII[Sar 1,Ile 4,Ile 8]-血管紧张素(一种AT 1 R的肽拮抗剂,可引起2-arrestin依赖性内化而不与G蛋白偶联)而不是通过氯沙坦(一种非肽中性拮抗剂)促进B2受体的缓激肽非依赖性内化。在AT 1 R四环素诱导的HEK细胞模型中,SII预处理是缓激肽诱导的钙信号传导的非竞争性拮抗剂,而氯沙坦没有作用。在原代大鼠VSMCs中获得了类似的结果。我们假设,AT 1 R拮抗剂,诱导受体内化可以作为缓激肽信号的变构拮抗剂的条件下,有利于形成异源二聚体,这表明它们在预防糖尿病肾病进展的效用。 公共卫生关系:了解糖尿病如何改变肾细胞的行为对于开发治疗糖尿病肾病的新治疗方法至关重要。该提案将研究受体-受体相互作用如何影响细胞信号传导。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Parker C. Wilson其他文献

Mutational fingerprints reconstruct human cell genealogies
突变指纹可重建人类细胞谱系
  • DOI:
    10.1038/s41581-021-00503-6
  • 发表时间:
    2021-10-27
  • 期刊:
  • 影响因子:
    39.800
  • 作者:
    Parker C. Wilson;Benjamin D. Humphreys
  • 通讯作者:
    Benjamin D. Humphreys
Single-cell genomics and gene editing: implications for nephrology
单细胞基因组学和基因编辑:对肾脏病学的影响
  • DOI:
    10.1038/s41581-018-0094-3
  • 发表时间:
    2018
  • 期刊:
  • 影响因子:
    41.5
  • 作者:
    Parker C. Wilson;B. Humphreys
  • 通讯作者:
    B. Humphreys
High Frequency of Triple Negative Breast Cancers Co-express p16 and SOX10 But Do Not Express AR.
三阴性乳腺癌的高频率同时表达 p16 和 SOX10 但不表达 AR。
  • DOI:
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    3.3
  • 作者:
    Esther C. Yoon;Parker C. Wilson;T. Zuo;M. Pinto;K. Cole;M. Harigopal
  • 通讯作者:
    M. Harigopal
Kidney and organoid single-cell transcriptomics: the end of the beginning
  • DOI:
    10.1007/s00467-018-4177-y
  • 发表时间:
    2019-01-04
  • 期刊:
  • 影响因子:
    2.600
  • 作者:
    Parker C. Wilson;Benjamin D. Humphreys
  • 通讯作者:
    Benjamin D. Humphreys
Predicting regulators of epithelial cell state through regularized regression analysis of single cell multiomic sequencing
通过单细胞多组学测序的正则回归分析预测上皮细胞状态的调节因子
  • DOI:
    10.1101/2022.12.29.522232
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Nicolas Ledru;Parker C. Wilson;Yoshiharu Muto;Yasuhiro Yoshimura;Haojia Wu;Amish Asthana;S. Tullius;S. Waikar;G. Orlando;B. Humphreys
  • 通讯作者:
    B. Humphreys

Parker C. Wilson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Parker C. Wilson', 18)}}的其他基金

The Single Cell Landscape of Early Human Diabetic Nephropathy
早期人类糖尿病肾病的单细胞景观
  • 批准号:
    10765844
  • 财政年份:
    2023
  • 资助金额:
    $ 4.26万
  • 项目类别:
The Single Cell Landscape of Early Human Diabetic Nephropathy
早期人类糖尿病肾病的单细胞景观
  • 批准号:
    10368354
  • 财政年份:
    2022
  • 资助金额:
    $ 4.26万
  • 项目类别:
Mechanisms of Diabetic Renal Damage: Role of the Kinin Receptors
糖尿病肾损伤的机制:激肽受体的作用
  • 批准号:
    8324065
  • 财政年份:
    2011
  • 资助金额:
    $ 4.26万
  • 项目类别:

相似海外基金

Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
  • 批准号:
    23H01982
  • 财政年份:
    2023
  • 资助金额:
    $ 4.26万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
  • 批准号:
    23KJ0116
  • 财政年份:
    2023
  • 资助金额:
    $ 4.26万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
  • 批准号:
    10682794
  • 财政年份:
    2023
  • 资助金额:
    $ 4.26万
  • 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
  • 批准号:
    10598276
  • 财政年份:
    2023
  • 资助金额:
    $ 4.26万
  • 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233343
  • 财政年份:
    2023
  • 资助金额:
    $ 4.26万
  • 项目类别:
    Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233342
  • 财政年份:
    2023
  • 资助金额:
    $ 4.26万
  • 项目类别:
    Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
  • 批准号:
    479363
  • 财政年份:
    2023
  • 资助金额:
    $ 4.26万
  • 项目类别:
    Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
  • 批准号:
    10681989
  • 财政年份:
    2023
  • 资助金额:
    $ 4.26万
  • 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
  • 批准号:
    2237240
  • 财政年份:
    2023
  • 资助金额:
    $ 4.26万
  • 项目类别:
    Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
  • 批准号:
    2305592
  • 财政年份:
    2023
  • 资助金额:
    $ 4.26万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了